Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

International Journal of Colorectal Disease

Volumn 26, Issue 2, 2011, Pages 143-151

  Formica, Vincenzo ^a,b   Palmirotta, Raffaele ^b   Del Monte, Girolamo ^c   Savonarola, Annalisa ^b   Ludovici, Giorgia ^b   De Marchis, Maria Laura ^b   Grenga, Italia ^a   Schirru, Michele ^a   Guadagni, Fiorella ^b   Roselli, Mario ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c San Raffaele Rocca di Papa Clinical Center   (Italy)

Author keywords

Bevacizumab; Metastatic colorectal cancer patients; Predictive markers; VEGF gene polymorphisms

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; VASCULOTROPIN;

5' UNTRANSLATED REGION; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; FISTULA; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GERM LINE; HAPLOTYPE; HUMAN; HYPERTENSION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERFORATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; RADIATION RESPONSE; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79951723590     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-010-1108-1     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Köhne CH, Lenz HJ (2009) Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 14:478-488
3. Heath VL, Bicknell R (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6:395-404
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
5. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622-2629
6. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M et al (2005) Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981-989 (Pubitemid 41430564)
7. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI et al (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.Nature 456:814-818
8. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-816 (Pubitemid 36231981)
9. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A et al (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369-3372 (Pubitemid 34651380)
10. García-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D et al (2007) Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 3:e29
11. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, Asomaning K et al (2008) VEGF polymorphisms and survival in early-stage nonsmall-cell lung cancer. J Clin Oncol 26:856-862 (Pubitemid 351398076)
12. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY et al (2008) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14:62-66
13. Hefler LA,MusteaA, Könsgen D, Concin N, Tanner B, Strick R et al (2007) Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13:898-901 (Pubitemid 46340365)
14. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647-3653 (Pubitemid 40685580)
15. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678
16. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA et al (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14:7554-7563
17. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
18. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786 (Pubitemid 350086481)
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. Köhne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3,825 patients. Ann Oncol 13:308-317 (Pubitemid 34704985)
21. Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio BG et al (2009) Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark 5:167-175
22. Schneider BP, Radovich M, Miller KD (2009) The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 15:5297-5302
23. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV et al (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260-264 (Pubitemid 34042036)
24. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232-1235 (Pubitemid 30611801)
25. Chen Y, Cicciarelli J, Pravica V, Hutchinson IV (2009) Longrange linkage on chromosome 6p of VEGF, FKBP5, HLA and TNF alleles associated with transplant rejection. Mol Immunol 47:96-100
26. Davis AH, Wang J, Tsang TC, Harris DT (2007) Direct sequencing is more accurate and feasible in detecting single nucleotide polymorphisms than RFLP: using human vascular endothelial growth factor gene as a model. Biol Res Nurs 9:170-178
27. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T et al (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130-3136 (Pubitemid 34791103)
28. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N et al (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-725 (Pubitemid 28436004)
29. Mohammadi M, Ollier W, Hutchinson I (2003) A functional association study of VEGF gene polymorphisms with VEGF expression by stimulated PBM cells. Hum Immunol 64:S125
30. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K et al (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-1639 (Pubitemid 34826636)
31. Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi V et al (1994) Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12:2687-2693 (Pubitemid 24379657)
32. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS et al (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24:217-227 (Pubitemid 46622051)